This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2001;286:2085.

	Since this article does not have an abstract, we have provided the first 122 words of the full text and any section headings.

The FDA has assessed the safety of patients undergoing certain medical procedures (such as blood transfusion, intravenous infusion of crystalloid fluids and drugs, hemodialysis, peritoneal dialysis, total parenteral nutrition, enteral nutrition, and cardiopulmonary bypass) involving exposure to di-(2-ethylhexyl) phthalate (DEHP), a compound used as a plasticizer for polyvinyl choloride medical devices.

The agency concluded that there is little risk of DEHP-mediated effects in adults receiving intravenous solutions or undergoing peritoneal dialysis. However, the results of studies in young animals have suggested that prolonged exposure of male neonates to devices that release DEHP may affect the development of their testes and normal spermatogenesis. The full assessment is available at http://www.fda.gov/cdrh/ost/dehp-pvc.pdf.

Bernard A. Schwetz, DVM,PhD
Acting Principal Deputy Commissioner
Food and Drug Administration

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?